In recent years, the proportion of biological drugs in the global pharmaceutical market has been close to 20%. The focus within the global pharmaceutical market has been gradually shifting from small molecule chemical drugs to biomacromolecules (biological drugs). It also appears that the trend is gradually expanding. Biological drugs are a broad class of pharmaceuticals generated by using principles and methods of biology, immunology, physical chemistry and pharmacology, etc. These drugs utilize the composition of various organisms, biological tissues as well as organs. Usually, biological drugs include genetic engineering drugs, antibody engineering drugs, blood products drugs and vaccines etc. Among these, antibody drugs are one of the fastest growing human therapeutic drugs. This increase in research and development has proved to be an effective treatment for many important diseases such as cancer, chronic inflammatory diseases, cardiovascular diseases, immune system diseases and infectious diseases. The antibody research and development also plays an important role in medicine and diagnostics.
Synbio Technologies’ Syno® Ab Antibody Platform utilizes molecular simulation technologies to provide antibodyde novo design and preparation services. We use this platform to simulate various biological behaviors of antibody molecules on the atomic level. We can analyze the antibody structure as a starting point to solve a series of problems such as the theoretical design of an antibody. The combination of the molecular simulation technology and experimental approach can help our customers effectively reduce the total cost of antibody R&D to effectively shorten the R&D cycle.
Powerful drug-like antibody bio-computation
Facilitate the development of “biologically superior” antibody drugs
Full human antibody library design
Proprietary software platforms
High-throughput antibody modeling
Effective antigen-antibody docking
Therapeutic antibodies have been licensed
Synbio Technologies’ Case Study
1. Methods of constructing antibody library
Extracted the H1, H2, H3, L1, L2 and L3 regions of the antibody from the PDB database
Created CDRs library
Assembled the CDR into the germline template
Created a complete antibody structure
2. Screening antibodies with specific antigens
Docked antigens with the antibody library
Sorted optimized antibodies based on interaction energy
Selected the best antibody based on evaluation
Antibody affinity modification
Synthesized the first 100 antibody sequences
3. Structural modeling method
Constructed an antibody backbone
Constructed the side chain of target protein
Constructed loop region
Final optimization of structure
4. Synbio Technologies’ antibody library model
Figure 1. Anti-antibody complex structure predicted by Synbio Technologies (the epitope is similar to the crystal structure of Figure 2)
Figure 2. Crystal structure of the antigen-antibody complex from the PDB database
6. Final data Designed 1~100 antibody sequences for antigen, all affinities were greater than 10-10M.
• Antibody sequence report • Structure analysis of specific targets (antigens) • Molecular simulation and molecular dynamics ordering • Computational ordering of antibody library (human or specific species) • Leads with the affinity greater than 10-9M • Antibody library or the synthesized leads antibodies
* Customers can provide the antigen name or gene ID directly; If you have antigen crystal structure, please contact us directly.
If you have any questions, please feel free to contact us anytime for assistance during business hours. Our experienced project managers will provide you with professional support to ensure the success of your project.
Reviews of Syno® Ab Antibody Design and Production